FDA considers using data from approved indications to support regular approvals of sNDAs based on intermediate endpoints December 08, 2017Vol.43 No.45By Matthew Bin Han Ong
Building a “hybrid” center by the Beltway, Trump pursues vision of a new national research network December 08, 2017Vol.43 No.45By Paul Goldberg
Drugs & Targets FDA approves adjuvant indication for Sutent in renal cell carcinoma December 07, 2017Vol.40 No.10
Ziopharm announces positive updated results of Ad-RTS-hIL-12 study in brain cancer December 07, 2017Vol.40 No.10
Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma December 07, 2017Vol.40 No.10
Novartis reports positive results from phase III trial of Kisqali for advanced or metastatic breast cancer December 07, 2017Vol.40 No.10
Phase III study shows Tecentriq and Avastin plus chemo reduced risk of disease progression or death in advanced lung cancer December 07, 2017Vol.40 No.10
Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy December 07, 2017Vol.40 No.10
